NOT-AR-20-017: Notice of Participation of the NIAMS in PAR-19-333, SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed.

Notice of Participation of the NIAMS in PAR-19-333, SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed.

Notice Number: NOT-AR-20-017

Key Dates
Release Date: March 16, 2020

Related Announcements
None

Issued by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

This notice is to inform SBIR/STTR applicants that NIAMS is participating, effective immediately, PAR-19-333: SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed.

The following sections of PAR-19-333 have been updated to reflect the participation of N?I?A?M?S? in this Notice:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Catalog of Federal Domestic Assistance (CFDA) Numbers

93.846

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Xibin Wang, Ph.D

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Phone: 301-451-3884

Email: wangx1@mail.nih.gov

Ms. Yen Thach

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Phone: 301-594-3505
Email: thachy@niams.nih.gov

With regard to PAR-19-333, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is interested in CRP applications from NIAMS Phase II funded applicants, provided they are within the NIAMS mission. However, NIAMS will not accept applications that include clinical trials. Applicants who wish to submit clinical trial applications to the NIAMS are encouraged to utilize one of the NIAMS clinical trial funding opportunities, which can be found on the NIAMS webpage: http://www.niams.nih.gov/Funding/Clinical_Research/clinical_main.asp.

Budgets may not exceed $400,000 total funding support in any year.

Inquiries

Please direct all inquiries to:

Xibin Wang, Ph.D
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-451-3884
Email: wangx1@mail.nih.gov

Ms. Yen Thach
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Phone: 301-594-3505
Email: thachy@niams.nih.gov